In 2020, Kortekaas and his colleagues highlighted that CD39+ T cells have specific tumor reactivity, and have further proven the importance of CD39 in identifying and isolating tumor-reactive T cells [44]. This evidence concerns the gene ENTPD1 and neoplasm.